2. Anti-infection
  3. SARS-CoV Dengue Virus
  4. Virapinib

Virapinib is a macropinocytosis inhibitor with antiviral activity. Virapinib exhibits broad-spectrum antiviral activity against SARS-CoV-2, monkeypox virus, tick-borne encephalitis virus, and Ebola pseudotyped vesicular stomatitis virus, and it enhances Dengue Virus infection. Virapinib blocks viral entry by inhibiting macropinocytosis, reduces syncytium formation in SARS-CoV-2-infected cells, and impairs cellular entry of SARS-CoV-2 variants. Virapinib upregulates the expression of genes related to sterol biosynthesis. Virapinib can be used in studies related to COVID-19, monkeypox, tick-borne encephalitis, and Ebola virus infection.

For research use only. We do not sell to patients.

Virapinib

Virapinib Chemical Structure

CAS No. : 1794091-10-3

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Virapinib Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Virapinib is a macropinocytosis inhibitor with antiviral activity. Virapinib exhibits broad-spectrum antiviral activity against SARS-CoV-2, monkeypox virus, tick-borne encephalitis virus, and Ebola pseudotyped vesicular stomatitis virus, and it enhances Dengue Virus infection. Virapinib blocks viral entry by inhibiting macropinocytosis, reduces syncytium formation in SARS-CoV-2-infected cells, and impairs cellular entry of SARS-CoV-2 variants. Virapinib upregulates the expression of genes related to sterol biosynthesis. Virapinib can be used in studies related to COVID-19, monkeypox, tick-borne encephalitis, and Ebola virus infection[1][2][3].

In Vitro

Virapinib (0.78-25 μM; 6 h pre-incubation; 72 h total incubation post-virus addition) inhibits SARS-CoV-2 S pseudotyped lentivirus infection in HEK293TACE2 cells in a dose-dependent manner, but has no effect on VSVg pseudotyped lentivirus infection[1].
Virapinib (0.5-10 μM; 6 h pre-incubation; 24 h total incubation post-virus wash-off) dose-dependently inhibits infection by the original SARS-CoV-2 in Vero E6 cells, with no cytotoxicity detected[1].
Virapinib (1-20 μM; 6 h pre-incubation; 24 h total incubation post-virus wash-off) dose-dependently inhibits infection by the original SARS-CoV-2, reduces syncytium formation in A549ACE2 cells, and shows no detectable cytotoxicity[1].
Virapinib (0.5-10 μM; overnight pre-incubation; 24 h total incubation post-virus infection) effectively reduces the infectivity of SARS-CoV-2 in 3D primary human hepatospheres[1].
Virapinib (5-25 μM; 16 h pre-incubation; 2 h dextran incubation) dose-dependently inhibits macropinocytosis in A549 cells and selectively blocks SARS-CoV-2 entry into A549ACE2 cells via the macropinocytosis pathway[1].
Virapinib (5-40 μM for tick-borne encephalitis virus and monkeypox virus; 10-25 μM for Ebola-pseudotyped vesicular stomatitis virus; 6 h pre-incubation) dose-dependently inhibits infections by tick-borne encephalitis virus, monkeypox virus, and Ebola-pseudotyped vesicular stomatitis virus in A549 cells. It shows no activity against Andes virus, only weak activity against adenovirus, and enhances dengue virus infection[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Virapinib Related Antibodies

Real Time qPCR[1]

Cell Line: MCF-7 cells, A549ACE2 cells
Concentration: 10 μM (MCF-7 RNA-seq); 10, 25 μM (A549ACE2 qRT-PCR)
Incubation Time: 6 h incubation (both cell lines)
Result: Showed significant upregulation of genes related to sterol biosynthesis, including HMGCS1, HMGCR, and MVK, in MCF-7 cells via RNA sequencing.
Identified 'steroid biosynthesis' as the most significantly induced pathway via KEGG pathway enrichment analysis.
Increased HMGCR, HMGCS1, and MVK mRNA levels in A549ACE2 cells via qRT-PCR, without altering total cellular cholesterol levels or cholesterol distribution.
Molecular Weight

448.60

Formula

C26H36N6O
CAS No.
SMILES

CC(CC1)CCN1C2=CC=C(C(N3CCC(C4=NC5=C(CCN(C)C5)C(NC)=N4)C3)=O)C=C2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Virapinib Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Virapinib1794091-10-3SARS-CoVDengue VirusSARS coronavirusDENVHEK293T cellsDengue virusEbola-pseudotyped vesicular stomatitis virustick-borne encephalitis virusmpox virusA549 cellsACE2Vero E6 cellsSARS-CoV-2macropinocytosisCOVID-19monkeypoxtick-borne encephalitisEbola virus infectionInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Virapinib
Cat. No.:
HY-161844
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.